Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia
https://doi.org/10.31363/2313-7053-2022-4-101-106
Abstract
A clinical case of the use of cariprazine in a patient with therapeutically resistant simple schizophrenia is considered. The debut and development of the disorder, pharmacological history are presented. The clinical and pharmacological aspects of the rationale for choosing cariprazine as an effective and safe drug for the treatment of schizophrenia with predominantly negative symptoms are analyzed.
About the Author
R. F. Nasyrova
V. M. Bekhterev National Research Center for Psychiatry and Neurology; P. P. Kashchenko Saint Petersburg Psychiatric Hospital № 1
Russian Federation
Russian Federation
Regina F. Nasyrova
St. Petersburg
References
1. Calabrese F., Tarazi F. I., Racagni G., Riva M A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020; 25 (3): 343–351. doi: 10.1017/S109285291900083X.
2. Cerveri G., Gesi C., Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019; 15: 1525–1535. doi: 10.2147/NDT.S201726
3. Fagiolini A., Alcalá J., Aubel T., et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann Gen Psychiatry. 2020; 19: 55. doi: 10.1186/s12991-020-00305-3.
4. Garcia S., Martinez-Cengotitabengoa M., Lopez-Zurbano S., et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016; 36 (4): 355–371. doi: 10.1097/JCP.0000000000000523
5. Girgis R. R., Slifstein M., D’Souza D., et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11) C]-(+)-PHNO. Psychopharmacology. 2016; 233 (19–20): 3503–3512. doi: 10.1007/s00213-016-4382-y.
6. Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018; 8 (11): 303–318. doi: 10.1177/2045125318781475.
7. Howes O. D., Thase M. E., Pillinger T. Treatment resistance in psychiatry: State of the art and new directions. Mol. Psychiatry.2022; 27: 58–72.
8. Huhn M., Nikolakopoulou A., Schneider-Thoma J., et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394 (10202): 939–951. doi: 10.1016/S0140-6736(19)31135-3
9. Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012; 27 (6): 432–436. doi: 10.1016/j.eurpsy.2011.02.015.
10. Insel TR. Rethinking schizophrenia. Nature. 2010; 468 (7321): 187–193. doi: 10.1038/nature09552.
11. Kanchanatawan B., Thika S., Anderson G., Galecki P., Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80 (Pt C): 168–176. doi: 10.1016/j.pnpbp.2017.06.031.
12. Kane J. M., Agid O., Baldwin M. L., Howes O., Lindenmayer J. P., Marder S., Olfson M., Potkin S. G., Correll C. U. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J. Clin. Psychiatry. 2019; 80: 2783.
13. Keks N., Hope J., Schwartz D., et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020; 34 (5): 473–507. doi: 10.1007/s40263-020-00718-4.
14. Laursen T. M. Life expectancy among personswith schizophrenia or bipolar affective disorder. Schizophr. 2011; 131: 101–104.
15. Laszlovszky I., Barabássy Á., Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety Adv Ther. 2021; 38 (7): 3652–3673. doi: 10.1007/s12325-021-01797-5.
16. Owen M. J., Sawa A., Mortensen P. B. Schizophrenia. Lancet. 2016; 388 (10039): 86–97. doi: 10.1016/S0140-6736(15)01121-6.
17. Perälä J., Suvisaari J., Saarni S. I., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64 (1): 19–28. doi: 10.1001/archpsyc.64.1.19.
18. Pillinger T., McCutcheon R. A., Vano L., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7 (1): 64–77. doi: 10.1016/S2215-0366(19)30416-X.
19. Rabinowitz J., Berardo C. G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. 2013; 150 (2–3): 339–342. doi: 10.1016/j.schres.2013.07.014.
20. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007; 64: 1123–1131.
21. Suttajit S., Pilakanta S. Predictors of quality of life among individuals with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 1371–1379. doi: 10.2147/NDT.S81024.
22. Vita A., Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018; 31 (3): 246–255. doi: 10.1097/YCO.0000000000000407
Review
For citations:
Nasyrova R.F. Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2022;56(4):101-106. (In Russ.) https://doi.org/10.31363/2313-7053-2022-4-101-106
Views:
595
Email this article 